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Research in context 4 
Evidence before the study  5 
In recent years viral meningitis has been recognised increasingly, and can be a significant cause 6 
of morbidity. Since the widespread introduction of conjugate vaccines against Haemophilus 7 
influenzae type B in 1992, Neisseria meningitidis serogroup C in 1999 and Streptococcus 8 
pneumoniae in 2002, the incidence of community acquired bacterial meningitis has been 9 
declining. This, in combination with increased molecular testing, means viruses are growing in 10 
relative importance as a cause of meningitis. Recent studies, using historical data, have also 11 
suggested changes in the aetiology of childhood viral meningitis over several decades.  12 
Variation in the incidence and aetiology of viral meningitis is reported. Some countries have a 13 
high incidence of herpesviruses, mainly herpes simplex type 2 and varicella zoster virus, whilst 14 
others rarely see them. We searched PubMed for “viral” AND “meningitis” AND “adults” with 15 
no date or language restrictions. 307 publications were returned, 22 were cohort studies 16 
looking at the aetiology of meningitis. Several papers describe the varying aetiology of 17 
meningitis but only 1 attempted to determine the incidence – in a cohort of Israeli soldiers. 18 
There has been a recent attempt to report the national incidence of viral meningitis in the UK, 19 
but this study only included laboratory confirmed cases, and did not distinguish between 20 
meningitis and encephalitis - where the aetiologies, treatment and prognoses are vastly 21 
different. No UK study has examined the incidence and aetiology of viral meningitis in adults. 22 
The outcomes following viral meningitis are also unclear, although subtle sequelae such as 23 
neurocognitive and sleep disorders have been described.  24 
Added value of this study 25 
This study takes a unique approach that combines the benefits of a prospective clinical 26 
epidemiological study with laboratory confirmed cases to estimate the incidence, aetiology 27 
and sequelae of viral meningitis in UK adults. It is the largest clinical study of adults with viral 28 
meningitis reported to date and gives us the first accurate incidence of viral meningitis, other 29 
causes and those with no known cause. It also describes the significant longer-term impact 30 
that viral meningitis has on quality of life, especially in regard to memory and mental health.  31 
Implications of all the available evidence 32 
Our findings demonstrate that viruses are the predominant cause of adult meningitis in the UK 33 
with enteroviruses and herpesviruses responsible for the majority of cases where a cause is 34 
found. Combined with previous studies this shows that there is significant geographical 35 
variation in the aetiology of viral meningitis. We highlight the burden that viral meningitis 36 
imposes on the health system and suggest areas where improvements could be made; a 37 
reduction in the length of hospitalisation and an increase in those with an aetiological diagnosis 38 
might be achieved through more rapid diagnostics.  Additionally, we add to the literature 39 
suggesting that viral meningitis has significant impact long after the patient has been 40 
discharged.   41 
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ABSTRACT  65 
Background 66 
Viral meningitis is being recognised increasingly but little is known about the frequency with 67 
which it occurs, or the causes and outcomes in the UK. We, therefore, aimed to determine the 68 
incidence, aetiology and sequelae in UK adults. Understanding this will improve the 69 
management of patients and assist in health service planning. 70 
Methods 71 
A multicentre prospective cohort study of adults with suspected meningitis was undertaken 72 
between 2011 and 2014 in England. Nested within this, in the NHS Northwest region, was an 73 
epidemiological study. We calculated the incidence of viral meningitis using Northwest patient 74 
data and generalised to estimate UK data. Patients self-reported outcomes for one year after 75 
admission. 76 
Findings 77 
1126 patients were enrolled. 638/1126 (57%) had meningitis: 231/1126 (36%) viral, 99/1126 78 
(16%) bacterial and 267/1126 (42%) unknown aetiology. 41/1126 (6%) had other causes. The 79 
estimated annual incidence of viral and bacterial meningitis was 2·73 and 1·24 per 100,000 80 
respectively. The median (IQR) length of stay for patients with viral meningitis was 4 (3,7) 81 
days, increasing to 9 (6,12) days in those treated with antivirals. Earlier lumbar puncture 82 
resulted in more patients having a specific cause identified. Patients with viral meningitis 83 
suffered a significantly decreased quality of life in the first year after illness.  84 
Interpretation 85 
Viruses are the most commonly identified cause of meningitis in UK adults, and led to 86 
substantial long-term morbidity. Delays in performing LP and unnecessary antivirals were 87 
associated with longer hospitalisations. Rapid diagnostics and rationalising treatments may 88 
reduce the burden of meningitis on health services. 89 
Funding: Meningitis Research Foundation; National Institute for Health Research  90 
 4 
 
Introduction 91 
As the incidence of bacterial meningitis decreases, the proportion of meningitis cases caused 92 
by viruses is increasing.1 The use of molecular diagnostics has also led to a greater recognition 93 
of neurological viral infections. 2 A seven-fold rise in reports of viral meningitis and 94 
encephalitis was seen in England and Wales between 2004 and 2013.2 Enteroviruses and 95 
herpesviruses are commonly reported causes of viral meningitis in adults, but their relative 96 
incidence varies in different countries. Finland reports a high incidence of herpesvirus 97 
meningitis, whereas Spain has a predominance of enteroviruses.3,4  98 
Identifying the cause of meningitis is important to improve clinical care, including reducing 99 
unnecessary antibiotics and antivirals. Patients with suspected viral meningitis are often treated 100 
with antibiotics whilst a diagnosis of bacterial meningitis is excluded. This results in patients 101 
receiving needless antibiotics and may extend their hospital stay.5 Although aciclovir, which 102 
has good in-vitro activity against many herpesviruses, is effective in encephalitis causes by 103 
herpes simplex virus (HSV) and varicella zoster virus (VZV), its role in acute meningitis 104 
caused by these viruses has never been determined.6 Aciclovir has no activity against 105 
enteroviruses. Viral meningitis is traditionally considered a benign, self-limiting illness,7 but 106 
there are increasing reports suggesting this may not be the case.8-10 107 
Recent trends in bacterial, fungal, and mycobacterial meningitis in the UK have been 108 
published,11 but the clinical burden of viral meningitis remains unknown. We, therefore, 109 
performed a national prospective observational study of adults admitted with suspected 110 
meningitis to determine the incidence, aetiology and sequelae.  111 
Methods 112 
Patients were recruited from 42 hospitals, throughout England, between September 2011 and 113 
September 2014, including all 24 acute hospitals in the Northwest administrative region of 114 
England. Patients were eligible if they were aged ≥16, had clinically suspected meningitis, and 115 
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either underwent a lumbar puncture (LP) or, if LP was contraindicated, had clinically suspected 116 
meningitis and a significant pathogen identified in either blood culture or on blood polymerase 117 
chain reaction (PCR). Those with ventricular devices were excluded. Case definitions are in 118 
table 1.  119 
Written informed consent was obtained. Clinical data were recorded on a secure online 120 
database (OpenClinica™). Ethical approval was given by the North Wales multicentre research 121 
ethics committee (reference 11/WA/0218). Research governance approval was given at each 122 
hospital. The study protocol can be accessed at www.braininfectionsuk.org/ukmeningitis.  123 
Estimation of meningitis incidence 124 
Incidence rates were estimated by dividing the number of patients recruited in the Northwest 125 
sites, in one year, by the total adult population of the same region. To estimate how many cases 126 
of meningitis had been missed in the prospective study, a retrospective review of laboratory 127 
records, spanning the first year of recruitment for each hospital, was performed in four hospitals 128 
within the Northwest (representing the variation in recruitment rates throughout the whole 129 
study). Cerebrospinal fluid (CSF) samples with a leukocyte count of >4 x 106 cells/L were 130 
identified from laboratory records and classified according to pathogen identified (or unknown 131 
if none found).  A proportional inflation, based on the total number of cases (those recruited 132 
and those missed) divided by the actual number recruited into the Northwest sites in the 133 
prospective study, was applied to the initial estimated Northwest incidence data.  This was used 134 
to estimate the population-standardised number of cases in the UK. Population data were 135 
sourced from the Office for National Statistics.12  136 
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Outcomes 137 
Clinical outcomes recorded included inpatient mortality and critical care use. Patient reported 138 
outcome measures assessed quality of life, neuropsychological functioning and symptom 139 
resolution. Quality of life was measured using EQ-5D-3L13 and SF-3614, both internationally 140 
validated tools. Other outcome measures used were the Aldenkamp and Baker 141 
neuropsychological assessment scale (ABNAS)15 and the Total Morbidity Score16  – both of 142 
which were developed for neurological disorders, namely epilepsy and meningitis 143 
(questionnaires in supplementary material).  EQ-5D-3L, SF-36 and ABNAS were assessed at 144 
6, 12, 24 and 48 weeks after admission. The Total Morbidity Score recorded resolution of 145 
symptoms for 3 weeks after admission.17 Quality adjusted life years (QALYs) were calculated 146 
from the EQ-5D-3L. There are no population level data for ABNAS, therefore questionnaires 147 
were sent to family/friends of the patient to act as a control group. 148 
Statistical Analysis 149 
T-tests were used for normally distributed continuous data.  Appropriate transformations were 150 
applied in the case of non-normally distributed continuous data.  If the transformed data were 151 
still not normally distributed Mann Whitney U or Kruskal-Wallis tests were used. Categorical 152 
data were analysed using Chi Square or Fisher’s Exact test. 95% confidence intervals (CI) were 153 
calculated using Byar’s method.18 To obtain 95% CI for the UK incidence a proportional 154 
inflation was applied to the Northwest data based on the retrospective data collection. Logistic 155 
regression was used to assess relationship between time to LP and getting a microbiologically 156 
proven diagnosis. The SF-6D, a single unit preference based measure, was obtained from the 157 
SF-36 and non-parametric Bayesian analysis was used with permission from the University of 158 
Sheffield, UK.19,20 A Bonferroni correction was applied to the ABNAS domains and a p-value 159 
of <0·008 was considered statistically significant; last observation carried forward was used 160 
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for missing data. Variables associated with symptom resolution were determined in univariate 161 
analyses using log-rank tests. Data were analysed using SPSS v21.  162 
Microbiological testing 163 
All CSF samples had microscopy and culture performed. CSF PCR was performed in the 164 
admitting hospitals, regional diagnostic centres, or University of Liverpool, for HSV-1 and 2, 165 
VZV and enteroviruses, along with PCR for Streptococcus pneumoniae and Neisseria 166 
meningitidis, following national recommendations.21  167 
Role of the funding source 168 
The funders of the study had no role in study design, data collection, analysis or interpretation, 169 
or writing of the report. The corresponding author had full access to all the data in the study 170 
and had final responsibility for the decision to submit for publication. 171 
Results 172 
1126 patients were enrolled, from throughout England, with 1113 included in the analysis 173 
(figure 1). 638/1126 (57%) fitted the meningitis case definition. The cause was proven viral in 174 
231/638 (36%), and bacterial in 99/638 (16%). The aetiology of all cases of meningitis are 175 
given in table 2. Enteroviruses were the most frequent viruses (n=127), accounting for 55% of 176 
all viral meningitis, and the single most common aetiology, accounting for 20% of all 177 
meningitis (127/638). 101/231 cases (44%) were caused by herpesviruses [HSV type 2 (n=52), 178 
VZV (n=43), HSV type 1 (n=3), Epstein-Barr virus (n=2) and cytomegalovirus (n=1)]. 179 
Streptococcus pneumoniae was the most common bacterial cause, responsible for 53/99 180 
bacterial cases (54%), but only 8% of all meningitis. There were 29 cases of meningococcal 181 
meningitis (48% serogroup B, 21% Y, 3% W and 28% unknown serogroup). There were four 182 
patients with cryptococcal meningitis (all HIV positive), and 11 with tuberculous meningitis. 183 
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A total of 267/638 (42%) patients with meningitis had no cause identified, of these, 200/267 184 
(75%) had a lymphocytic CSF (>50% lymphocytes) – classified as ‘lymphocytic meningitis – 185 
unknown aetiology’, and 41/267 (15%) had neutrophil predominance (≥50% neutrophils) – 186 
classified as ‘neutrophilic meningitis – unknown aetiology’. The predominant leukocyte type 187 
was unknown in 26/267 patients with no identified cause (10%). Clinical features are shown in 188 
table 3. 189 
Using both the prospective and retrospective data, from the Northwest sites, the incidence of 190 
viral meningitis and bacterial meningitis in UK adults was estimated to be 2·73 and 1·24 per 191 
100,000 per year, respectively (table 4). When all cases were considered, including those with 192 
no identified aetiology, the annual incidence of all meningitis in UK adults was 13·47 per 193 
100,000.  194 
Nine-hundred-and-one (81%) of 1113 patients had neurological imaging, with the majority 195 
[776/1113 (70%)] before LP. Only 90/776 (12%) had an indication for imaging prior to LP, as 196 
recommended in national guidelines (box).22 The most common indications were, Glasgow 197 
coma scale ≤12 in 54/776 (7%) and seizures in 36/776 (5%); five patients had papilloedema 198 
and eight had focal neurological findings. The median (IQR) time from admission to 199 
antibiotics, and to LP, were 2 [0,10 (n=237)] and 8 [3,22 (n=299)] hours respectively, in those 200 
who did not have imaging prior to LP, compared with 3 [1,11 (n=563)] and 18 [9,30 (n=776)] 201 
hours in those who did (p=0·004 and <0·0001 respectively). The median (IQR) time from 202 
admission to LP was longer in the lymphocytic meningitis – unknown aetiology group [21 203 
(9,37·5) hours] than those with proven viral meningitis [13 (7,23) hours], proven bacterial 204 
meningitis [13 (4·5,23) hours] and neutrophilic meningitis- unknown aetiology [15 (7,22·5) 205 
hours; p=<0·0001, <0·0001 and 0·008 respectively]. The median (IQR) time to LP for all 206 
patients was 17 (8,29) hours. The chances of having a pathogen detected in viral meningitis 207 
was reduced by 1% for every hour delay in LP after admission [OR 0.988 (95% CI 0.982-208 
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10.995), p=0·001] (figure 2). For bacterial meningitis there was also a reduction of 1% for each 209 
hour delay, but this was not statistically significant [OR 0.995 (95% CI 0.989-1.002), p=0·16]. 210 
24/99 (25%) patients with bacterial meningitis were diagnosed by molecular methods alone. 211 
The role of different tests in diagnosing bacterial meningitis is shown in figure S1.  212 
One-hundred-and-thirty-nine (60%) of 231 patients with viral meningitis had at least one dose 213 
of an antiviral (aciclovir and/or valaciclovir) and 51/139 (37%) received a course, defined as ≥ 214 
five days. 42/98 (43%) of those with HSV or VZV meningitis received a course of antivirals 215 
with a median (range) duration of ten (5-30) days. The treatment regime varied considerably 216 
(figure S2).  Patients in whom enterovirus meningitis was diagnosed were less likely to receive 217 
antiviral drugs, where they would have no effect, than those where no aetiology was identified 218 
[8/127 (6%) versus 50/248 (20%) (p=<0·0001)]. Most patients [160/231 (69%)] with proven 219 
viral meningitis also received at least one dose of antibiotics (median duration, one day) and 220 
199/267 (75%) of those without an aetiological cause received at least a single dose. 328/454 221 
(72%) patients who did not have meningitis received empirical antibiotics. 222 
The median (IQR) length of stay for patients with viral meningitis was 4 (3,7) days. Patients 223 
with herpesvirus meningitis stayed in hospital longer than patients with enteroviral meningitis 224 
[6 (3·75,10) days vs, 3·5 (3,5) days, p=<0·0001] and those with VZV meningitis stayed longer 225 
than those with HSV [8 (5,11) days vs 5 (3,8) days, p=0·02]. Those who received antivirals 226 
were in hospital longer than those who did not [8 (5,11) days vs. 3 (2,5) days, p=<0·0001]. 227 
Those with lymphocytic meningitis – unknown aetiology stayed in hospital slightly longer than 228 
those with proven viral meningitis [5 (3,8·5) days versus 4 (3,7), p=0·09]. Seven patients died 229 
before discharge, five of whom had meningitis - three pneumococcal, one tuberculous and one 230 
malignant meningitis. 91 patients required admission to intensive care; 52/91 (57%) had 231 
bacterial meningitis, with 37/52 (71%) having pneumococcal disease. No patients with viral 232 
meningitis died or required admission to intensive care.  233 
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Quality of life was reduced in all aetiological groups, at all times points, when compared with 234 
the UK population (figure 3). EQ-5D-3L utility scores were similar for both viral and bacterial 235 
meningitis. They were significantly lower for HSV meningitis, compared with the other viral 236 
aetiologies, at 6 weeks after discharge (p=0·004). 12/14 (86%) patients with HSV meningitis 237 
who returned the questionnaires, had problems with anxiety or depression at six weeks (figure 238 
S3). Supporting, and confirming, the EQ-5D-3L data, all groups had worse SF-6D scores than 239 
UK norms (Figures S4 and S5). The average QALY for patients with viral meningitis, over the 240 
first year, was 0.72. Compared with the age matched UK population, patients with viral 241 
meningitis suffered a loss of 0.2 QALYs in that first year (figure S6). There was no significant 242 
difference in time to resolution of headache between viral meningitis and bacterial, as measured 243 
by the Total Morbidity Score (7 versus 8 days, p= 0·09) (table S1). Patients with viral 244 
meningitis had significantly worse ABNAS scores then healthy controls at all four time points 245 
in the year after illness (figure S7 and table S2).  246 
Discussion 247 
This study provides the first estimate of the incidence of viral meningitis in UK adults. Using 248 
clinical and laboratory data we estimate the annual incidence of confirmed viral meningitis in 249 
UK adults to be almost 3 per 100,000. Previous UK studies of meningitis have been based on 250 
coding data or laboratory reports, missing those that have no aetiological diagnosis.1,2,11 We 251 
have estimated the incidence of all  meningitis to be 13·47 per 100,000. Previously, a similar 252 
estimate of the incidence of meningitis in the US was estimated to be 27·9 per 100,000.23 This 253 
was in the late 20th century and included adults and children. It is likely to be substantially 254 
lower now, given the impact of immunisation.24  255 
Enteroviruses were the most common aetiology, accounting for just over 50% of all confirmed 256 
viral meningitis.  Herpesviruses accounted for just under 50%, significantly more than in 257 
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previous studies from other countries.4 This may, in part, be explained by different rates of 258 
HSV-2 seroprevalence – known to be higher in northern Europe than southern.25 259 
In line with other studies a significant proportion of our patients had no cause identified.3,4 This 260 
poses a challenge on how to categorise them. There have been several attempts at diagnostic 261 
algorithms each of which has its limitations, and none of which has become routine clinical 262 
practice.26 We chose a pragmatic and objective classification, used on the wards daily, based 263 
on predominant CSF leukocyte type. We recognise this does not equate to presumed viral or 264 
bacterial meningitis, and indeed, 18% of patients with bacterial meningitis had a lymphocytic 265 
CSF and 7% of viral meningitis (mostly enteroviral) had a neutrophil predominance. 266 
Nevertheless, it is a helpful way of providing an initial patient classification. The patients with 267 
lymphocytic meningitis – unknown aetiology had a significantly longer time from admission to 268 
LP, suggesting that an early LP may increase the number of patients having an aetiology 269 
identified. It may be, as is known in enterovirus meningitis, that there is a change in the immune 270 
response from neutrophils early on, to lymphocytes later.   271 
Diagnosing a specific virus is known to reduce inappropriate antibiotic usage, length of hospital 272 
stay, and hospitalisation costs.5,7 We have also shown it reduces the unnecessary use of 273 
antivirals. 21% of patients with lymphocytic meningitis – unknown aetiology received a course 274 
of aciclovir or valaciclovir compared with 6% of patients diagnosed with enteroviral 275 
meningitis, where aciclovir would have no effect. With no evidence base to support aciclovir 276 
treatment in HSV or VZV meningitis, as has been highlighted previously, there was much 277 
variation in practice.6 Almost half of these patients received antivirals, resulting in longer 278 
hospital admissions. Most patients who had antivirals had intravenous treatment, necessitating 279 
inpatient care. A trial of aciclovir, or valaciclovir, in acute herpesvirus meningitis would help 280 
determine best practice. Improving diagnostic testing so more patients can have a specific 281 
aetiology determined quickly could reduce unnecessary antimicrobials and therefore, reduce 282 
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hospital stays and other investigations7. Full diagnostic accuracy and cost-effectiveness studies 283 
should be performed before any new tests are introduced. 284 
Once viral meningitis is diagnosed efforts should focus on symptomatic treatment and 285 
expediting discharge. Theoretically this can happen quickly; a LP and the diagnostic PCR can 286 
be done within a few hours. However, in our study the median time from admission to LP was 287 
17 hours, and the median length of hospitalisation, four days. The prolonged time from 288 
admission to LP is concerning. International guidelines all stress the urgency of the diagnostic 289 
LP;26,27,28 delays decrease pathogen yield and can increase mortality.29-31 The length of time it 290 
took to get an LP may explain why a large proportion of patients had no aetiological cause 291 
identified in our study, especially those with viral meningitis where there was a highly 292 
significant association between time to LP and likelihood of getting a definitive diagnosis. 293 
Unnecessary neuroimaging may have contributed to the delays. This has been highlighted 294 
previously as a risk factor for increased mortality in bacterial meningitis.31,32 In the UK the 295 
requirement for all patients to be transferred out of the emergency department within four hours 296 
creates an unintended pressure causing key investigations such as LP, to be deferred until 297 
patients have been admitted to a ward. Additional delays in diagnosis occur if the CSF is sent 298 
to an offsite laboratory for analysis. Because of sample batching and transport it may take 299 
several days from LP to result, despite the actual rapidity of the test. If PCR is performed 300 
locally, seven days a week on receipt of a single CSF sample, the length of hospitalisation can 301 
be reduced to less than a day, resulting in significant cost savings.7 In order to make this saving 302 
relatively simple changes are required, such as doing LPs in the emergency department, and 303 
having diagnostics available on-site .  304 
Despite viral meningitis often being referred to as benign and self-limiting,7 we found long 305 
term neuropsychiatric sequelae, particularly anxiety, depression and neurocognitive 306 
dysfunction. Whilst patients with bacterial meningitis have more severe disease initially in 307 
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terms of critical care need and mortality, over the longer term all patients with meningitis, viral 308 
and bacterial, had sequelae affecting quality of life including significant problems with memory 309 
and mental health.  310 
There are limitations to our study. Due to its prospective nature, we risked not recruiting all 311 
eligible patients. We accounted for this by identifying cases retrospectively in the laboratories 312 
and then applying an uplift. We extrapolated the incidence from the Northwest to the whole 313 
country, which assumes there is minimal variation in incidence throughout the UK. We found 314 
the incidence of pneumococcal, meningococcal and all viral meningitis was similar to other 315 
UK based studies that used only laboratory data.2,11 Relying on CSF analysis excluded patients 316 
who did not have a LP but allowed us to accurately define our cohort. Our definitions may have 317 
missed some cases of viral meningitis with a CSF cell count of less than 5 x 106 cells/L or those 318 
who did not have a LP. It is known that children, especially neonates, can have clinical features 319 
of meningitis, with viruses detected in the CSF, without a CSF pleocytosis.33 This is less well 320 
recognised in adults. 58% of our patients who had a LP had meningitis, which is higher than 321 
other studies,34 and may indicate a higher threshold for LP in the UK. Given that we looked 322 
only for the most common viruses we cannot exclude the possibility that other rare, novel or 323 
emerging viruses might have been responsible for some cases. However, previous attempts 324 
using novel techniques have failed to identify significantly more pathogens than routine 325 
approaches.35  326 
In summary, this study shows that viruses are the major cause of meningitis in UK adults, and 327 
impose a significant clinical burden – both acutely and longer term. To improve management 328 
and reduce costs there is a pressing need for better diagnostic practices including rapid tests 329 
and the delivery of high quality viral diagnostics locally. Treatments also need to be developed 330 
and evaluated that may allow quicker recovery, and fewer longer term sequelae.  331 
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Tables 405 
 406 
Table 1. Case Definitions 
 
Meningitis Patient with symptoms consistent with meningitis and a cerebrospinal fluid leukocyte count >4 x 106 cells/L*/** 
 
Viral meningitis  
 
Meningitis 
AND 
Positive CSF PCR for a viral pathogen 
OR 
Detection of an appropriate pathogen by either throat swab, rectal swab or serology^ 
 
Bacterial meningitis 
 
Meningitis** 
AND 
Detection of an appropriate pathogen from either blood or CSF by PCR, culture or gram stain. 
OR 
Patient with symptoms consistent with meningitis (who did not have an LP) 
AND 
Detection of an appropriate pathogen from blood by PCR, culture or gram stain 
Lymphocytic meningitis – 
unknown aetiology 
 
Meningitis 
AND 
CSF lymphocytes > 50% of total leucocyte count 
AND 
No cause identified 
 
Neutrophilic meningitis – 
unknown aetiology 
 
Meningitis 
AND 
CSF lymphocytes ≤ 50% of total leucocyte count 
AND 
No cause identified 
 
Undifferentiated 
meningitis 
Meningitis 
AND 
No CSF leucocyte differential was performed, and no cause identified 
 
Encephalitis (adapted from 
reference 36) 
Altered consciousness for >24 hours (including lethargy, irritability or a change in personality) with no other cause 
found  
With 2 or more of the following  
Fever or history of fever (≥38 degrees Celsius) during the current illness; Seizures and/or focal neurological signs 
(with evidence of brain parenchyma involvement); CSF pleocytosis (>4 x 106 cells/L); EEG suggesting encephalitis; 
Neuroimaging suggestive of encephalitis (CT or MRI)  
 
Tuberculous meningitis Identification of Mycobacterium tuberculosis in the CSF or treated as tuberculous meningitis for ≥ 2 months 
Fungal meningitis Identification of fungus in the CSF with clinically suspected meningitis 
 
Meningitis – other cause Meningitis with a cause other than meningeal infection identified 
 
*corrected for CSF red cell count by 1:700 
** patients with bacterial and fungal meningitis who had symptoms consistent with meningitis and a pathogen identified in their CSF were 
classified as having meningitis even if there was no CSF pleocytosis 
CSF – cerebrospinal fluid; PCR – polymerase chain reaction; EEG – electroencephalogram; CT – computed tomography; MRI – magnetic 
resonance imaging 
^ Cytomegalovirus, Epstein Barr virus and HIV serology 
407 
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Table 2. Aetiology of meningitis in UK adults N % 
Viral 
Enteroviruses 127 19.9 
Herpes Simplex Virus type 2 52 8.2 
Varicella Zoster Virus 43 6.7 
Herpes Simplex Virus type 1 3 0.5 
Epstein Barr Virus 2 0.3 
Cytomegalovirus 1 0.2 
Measles 1 0.2 
Mumps 2 0.3 
Total 231 36.2 
 
Bacterial 
Streptococcus pneumoniae 53 8.3 
Neisseria meningitidis 29 4.5 
Haemophilus influenzae 5 0.8 
Listeria monocytogenes 3 0.5 
Streptococcus pyogenes 1 0.2 
Streptococcus agalactiae 1 0.2 
Streptococcus oralis 1 0.2 
Mycoplasma pneumoniae 1 0.2 
Fusobacterium sp 1 0.2 
Escherichia coli 1 0.2 
Pseudomonas sp. And Klebsiella sp 1 0.2 
Positive 16S PCR with no product identified 2 0.3 
Total 99 15.5 
 
Mycobacterial   
Mycobacterium tuberculosis 11 1.7 
 
Fungal   
Cryptococcus neoformans 4 0.6 
 
Infectious causes originating outside the CNS   
Neurosyphilis 2 0.3 
Endocarditis with cerebral emboli/epidural collection 2 0.3 
Infected spinal stimulator 1 0.2 
Subdural empyema 1 0.2 
Total 6 1 
 
Non-infectious causes of CSF pleocytosis   
Cerebral haemorrhage 3 0.5 
Cerebral infarct 2 0.3 
Idiopathic intracranial hypertension 2 0.3 
Malignancy 2 0.3 
Post-surgical 2 0.3 
Cluster headache 1 0.2 
Epidural haematoma 1 0.2 
Lymphocytosis hypophysitis 1 0.2 
Migraine 1 0.2 
Miller Fisher Syndrome 1 0.2 
Multiple Sclerosis 1 0.2 
Neurosarcoidosis 1 0.2 
Seronegative uveomeningeal syndrome 1 0.2 
Sjogren's syndrome 1 0.2 
Total 20 3 
Unknown cause 267 41.8 
Grand Total 638 100 
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 Table 3. Clinical features of study population by aetiology 
          Bacterial meningitis      Viral meningitis       Unknown aetiology 
          --------------------------------------------------------------   ---------------------------------------------------------------------------------    --------------------------------- 
  All patients (n=1117) 
Not meningitis 
(n=454) 
All meningitis 
(n=637) P value* 
All bacterial 
meningitis 
(n=99) 
Pneumococcal 
meningitis (n=53) 
Meningococcal 
meningitis (n=28) 
P value 
** 
All viral 
meningitis 
(n=231) 
Enteroviral 
meningitis 
(n=127) 
HSV 
meningitis 
(n=55) 
VZV 
meningitis 
(n=43) 
P value# P value## 
Purulent 
meningitis 
(n=41) 
Lymphocytic 
meningitis 
(n=199) 
Age 34 (25,49) 36 (25,48) 34 (25,49) 0.788 56 (34,65) 60 (42.5,65.5) 44 (19.5,57) 0.002 32 (24,42) 30 (24,36) 34 (26,50) 37 (25,53) 0.004 <0.001 33 (23,48.5) 33 (27,45.5) 
Percentage female  704/1117 (63) 302/454 (66) 388/637 (61) 0.065 49/99 (49.5) 29/53 (55) 11/28 (39) 0.15 152/231 (66) 79/127 (62) 45/55 (82) 24/43 (56) 0.01 0.006 24/41 (58.5) 128/199 (64) 
Neck stiffness   603/1079 (56) 238/436 (55) 348/616 (56.5) 0.571 39/92 (42) 19/47 (40) 11/29(38) 0.83 149/229 (65) 80/126 (63.5) 43/54 (80) 22/42 (52) 0.01 <0.001 20/36 (56) 100/179 (56) 
Headache   1025/1096 (93.5) 415/446 (93) 587/623 (94) 0.445 82/92 (89) 43/47 (91.5) 26/29 (90) 1 229/231(99) 127/127 (100) 54/54 (100) 42/43 (98) 0.19 <0.001 36/41(88) 190/197 (96) 
Photophobia   747/1083 (69) 320/443 (72) 415/613 (68) 0.119 39/91 (43) 18/47 (38) 14/29 (48) 0.39 185/231 (80) 111/127 (87) 42/55 (76) 28/43 (65) 0.004 <0.001 20/35(57) 121/178 (68) 
History of rash  139/974 (14) 75/437 (17) 78/607 (13) 0.062 21/93 (23) 5/48 (10) 14/29 (48) <0.001 29/228 (13) 11/125 (9) 6/54 (11) 11/43 (26) 0.02 0.03 2/33 (6) 14/175 (8) 
Confusion  217/1077 (20) 65/436 (15) 145/615 (24) <0.001 54/95 (57) 36/50 (72) 10/29 (34.5) 0.001 22/227 (10) 10/125(8) 5/53(9) 7/43(16) 0.28 <0.001 12/38 (32) 35/159 (18) 
Sore throat  189/1048 (18) 109/427 (25.5) 77/594 (13) <0.001 12/90 (13) 4/46 (9) 5/28 (18) 0.285 31/221 (14) 22/124(18) 6/50(12) 1/41 (2) 0.04 0.936 8/36 (22) 23/189 (12) 
Vomiting  601/1088 (55) 229/441 (52) 359/622 (58) 0.061 62/94 (66) 28/48 (58) 24/29 (83) 0.03 123/229 (54) 66/126 (52) 26/54 (48) 29/43 (67) 0.14 0.051 24/39 (62) 118/196 (60) 
Diarrhoea  107/1049 (10) 42/429 (10) 63/596 (11) 0.684 17/92 (18.5) 6/47 (13) 5/29 (17) 0.59 25/220 (11) 13/120 (11) 4/53 (8) 7/42 (17) 0.4 0.093 4/33 (12) 14/190 (7) 
Myalgia  363/1029 (35) 173/420 (41) 182/585 (31) 0.001 21/90 (23) 4/46 (9) 12/29 (45) <0.001 73/221 (33) 38/124 (31) 22/51 (43) 9/40 (23) 0.1 0.127 16/36 (44) 57/179 (32) 
Genital Ulcers  8/941 (1) 3/369 (1) 5/550 (1) 0.878 0/88 (0) 0/44 (0) 0/29 (0) n/a 5/206 (2) 0/112 (0) 5/48 (10) 0/40 (0) 0.001 0.188 0/32 (0) 0/167 (0) 
Seizures  46/1069 (4) 25/432 (6) 20/613 (3) 0.048 8/96 (8) 6/51 (12) 1/29 (3) 0.41 0/226 (0) 0/126 0/51 0/43 n/a <0.001 4/35 (10) 3/189 (2) 
Previous history of 
meningitis   117/1077 (11) 44/437 (10) 72/615 (12) 0.396 11/95 (12) 9/50 (18) 1/29 (3) 0.08 24/226 (11) 7/126 (6) 15/53 (28) 2/41 (5) <0.001 0.894 2/39 (5) 24/193 (12) 
Fever (>38⁰C) 260/1117 (23) 110/454 (24) 143/618 (23) 0.511 39/99 (39) 26/53 (49) 7/29 (24) 0.03 43/226 (19) 28/127 (22) 8/55 (14.5) 6/43 (14) 0.33 <0.001 8/38 (21) 39/154 (20) 
Kernig’s positive  104/472 (22) 51/203 (25) 49/259 (19) 0.113 9/25 (36) 4/12 (33) 2/7 (29) 1 27/116 (23) 14/70 (20) 11/31 (35.5) 2/11 (18) 0.269 0.242 1/17 (6) 7/78 (9) 
Brudzinski’s positive  30/184 (16) 11/72 (15) 18/108 (17) 0.839 4/12 (33) 2/6 (33) 1/3 (33) 1 10/41 (24) 5/26 (19) 5/10 (50) 0/4 (0) 0.123 0.712 0/11 (0) 3/34 (9) 
GCS  15 (15,15) 15 (15,15) 15 [15,15] 0.807 14 [10,15] 11 (9,14) 15 (14,15) <0.001 15 [15,15] 15 (15,15) 15 (15,15) 15 (15,15) 0.25 <0.001 15 (15,15) 15 (15,15) 
Blood WCC (x 109/L) 9.4 (7.1,12.9) 9.3 (6.8,12.9) 9.45 (7.4,13) 0.252 16.39 (12.52,21.9) 16.9 (13.7,21.5) 17.8 (11.1,24.4) 0.74 8.8 (7.1,10.6) 8.8 (6.9,10.6) 9.4 (7.9,12) 8.6 (6.4,10.3) 0.07 <0.001 9.6 (7.9,13.9) 8.9 (7.1,11.8) 
CRP (mg/L) 49.5 (22,122) 55 (28,120.5) 42.5 (19,123) 0.034 164 (67,261) 169 (69,263) 184 (111,295) 0.34 20 (14.5,37.5) 20 (16,38.5) 11 (10,28) 25.5 (18.5,76) 0.02 <0.001 38 (15,148) 31 (18,82) 
CRP <10 41% 163/454 (36) 278/637 (44)  6/99 (6) 10% 0% 0.15 125/231 (54) 35% 83% 90% <0.001 <0.001 24% 53% 
CSF Opening 
Pressure (cm CSF) 20 (15,25.5) 18 (15,21) 22 (16,28) 1 30 (21,40) 36 (26,40) 30 (18,35) 0.07 21 (16.25,27) 21 (15,26) 22 (20,29) 25 (16,30) 0.34 <0.001 23.5 (21,29.5) 20 (15,25) 
CSF leukocyte count 
(x106/L) 77 (5,306) n/a 155 (44,450) <0.001 
1800 
(377,4850) 2180 (668,4340) 2000 (480,7175) 0.81 188 (67,355) 118 (44,218) 374 (225,718) 249 (106,450) <0.001 <0.001 133 (29,730) 102 (34,255) 
CSF neutrophil 
percentage 5 (0,37) n/a 10 (0,47) <0.001 90 (66,95) 90 (68,96) 90 (79,98) 0.62 5 (0,14.25) 8 (2,22) 1 (0,10) 0 (0,10) <0.001 <0.001 80 (60,90) 4 (0,10) 
CSF protein (g/L) 0.53 (0.32,0.98) 
0.32 
(0.25,0.45) 
0.81 (0.53, 
1.38) <0.001 4 (2,6.68) 5.63 (3.1,8.12) 3.0 (1.17,6.67) 0.03 0.76 (0.54,1.12) 
0.57 
(0.45,0.75) 1.14 (0.9,1.32) 1.18 (0.89,1.4) <0.001 <0.001 0.8 (0.5,1.44) 0.68 (0.49,1.0) 
CSF glucose (mmol/L) 3.2 (2.8,3.7) 3.5 (3.2,3.9) 3 (2.5,3.5) <0.001 1.1 (0.3,2.7) 0.5 (0.2,1.7) 1.1 (0.4,2.8) 0.02 3 (2.7,3.4) 3.1 (2.8,3.5) 3.0 (2.7,3.4) 2.85 (2.5,3.23) 0.009 <0.001 3.3 (2.7,3.9) 3.1 (2.8,3.4) 
CSF: serum glucose 
ratio 
0.58 
(0.46,0.67) 0.63 (0.57,0.7) 
0.52 
(0.4,0.62) <0.001 0.12 (0.03,0.41) 0.04 (0.01,0.26) 0.15 (0.05,0.42) 0.02 0.56 (0.49,0.63) 
0.58 
(0.53,0.64) 
0.52 
(0.48,0.61) 
0.54 
(0.45,0.63) 0.104 <0.001 0.57 (0.41,0.66) 0.57 (0.46,0.66) 
 Values are median [IQR] for continuous data and N/n. evaluable (%) for categorical data. 
 GCS – Glasgow Coma Scale; WCC – White cell count; CRP – C-reactive protein; CSF – cerebrospinal fluid; HSV – Herpes Simplex Virus; VZV –Varicella zoster virus. 
 *Significance values comparing all meningitis and not meningitis. #Significance values comparing HSV, VZV and enteroviral. ## Significance values comparing all proven bacterial and all proven viral 
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Table 4. Estimated incidence of community acquired meningitis in UK adults by aetiology 
Aetiology  Total number of 
patients recruited in 
Northwest sites over 
duration of study 
Estimated 
number of 
patients in the 
Northwest in 
one year~  
Estimated annual 
incidence (95% CI) in 
Northwest* based on 
numbers recruited 
(per 100,000)  
Proportional 
increase # 
Estimated annual 
corrected Incidence 
(95% CI) (per 
100,000 population) 
Estimated 
number of cases a 
year in the UK 
(95% CI) 
             
Enteroviral meningitis 85 39 0.70 (0.49-0.95) 2.25 1.57 (1.11-2.14) 802 (567-1091) 
Herpes simplex virus meningitis 38 18 0.31 (0.19-0.51) 2.5 0.78 (0.48-1.27) 399 (242-647) 
Varicella zoster virus meningitis 29 13 0.24 (0.12-0.4) 1.5 0.36 (0.19-0.59) 182 (94-303) 
Total confirmed viral meningitis 154 71 1.27 (0.99-1.6) 2.15 2.73 (2.13-3.44) 1389 (1084-1750) 
Streptococcus pneumoniae 
meningitis 
26 13 0.23 (0.12-0.39) 4.5 1.04 (0.53-1.73) 529 (268-884) 
Neisseria meningitidis meningitis 15 7 0.12 (0.04-0.25) 1 0.12 (0.04-0.25) 63 (23-125) 
Total confirmed bacterial meningitis 47 22 0.39 (0.24-0.58) 3.2 1.24 (0.76-1.87) 631 (390-951) 
Meningitis – unknown aetiology 176 81 1.45 (1.15-1.8) 7.3 10.58 (8.4-13.14) 5390 (4277-6695) 
All meningitis** 385 178 3.17 (2.72-3.67) 4.25 13.47 (11.55-15.59) 6864 (5886-7944) 
~based on sites recruiting patients for a median duration of 26 months *Calculated using Office of National Statistics mid-2012 population data and the Northwest having 11% 
of the UK population  
# based on number of cases missed in one year in Northwest sentinel sites **Includes unknown aetiology and causes other than bacteria and viruses 
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Box. Indications for neuroimaging prior to lumbar puncture 
Glasgow Coma Scale ≤ 12 
Uncontrolled seizures 
Papilloedema 
Focal Neurological signs 
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